查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1319036

PD-1 和 PD-L1 抑制劑市場：按產品、分銷管道 - 2023-2030 年全球預測

PD-1 & PD-L1 Inhibitors Market by Product, Distribution Channel - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2023 年，全球 PD-1 和 PD-L1 抑制劑市場將大幅成長，達到 371.1 億美元，年複合成長率為 20.52%，預計到 2030 年將達到驚人的 1,376.5 億美元。

FPNV定位矩陣

FPNV定位矩陣對於評估全球PD-1和PD-L1抑制劑市場至關重要。透過檢查業務策略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使您能夠根據您的特定需求做出明智的資訊。這種進階分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市佔率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對總收入、基本客群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、累積和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、未開發地區、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通膨的累積影響。

5.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。

6. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1.PD-1和PD-L1抑制劑的全球市場規模和預測是多少？

2.在預測期內，COVID-19對全球PD-1和PD-L1抑制劑市場的阻礙因素和影響為何？

3.預測期間全球PD-1和PD-L1抑制劑市場有哪些產品/細分市場/應用/領域值得投資？

4.PD-1和PD-L1抑制劑全球市場的競爭策略是什麼？

5.PD-1和PD-L1抑制劑全球市場的技術趨勢和法律規範是什麼？

6.全球PD-1和PD-L1抑制劑市場主要廠商的市佔率是多少？

7. 哪些型態和策略性措施被認為適合進入PD-1和PD-L1抑制劑的全球市場？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

  • 市場動態
    • 促進因素
      • 老年人口增加導致癌症罹患率增加
      • 增加患者支持計劃的存在
      • 公眾意識不斷提高，醫療費用不斷上漲
    • 抑制因素
      • 昂貴的癌症免疫療法
    • 機會
      • pd1 和 pdl1 抑制劑的研究活動增加
      • 癌症篩檢的技術創新和進步
    • 任務
      • 嚴格法規場景
  • 市場趨勢
  • COVID-19 的累積影響
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範
  • 客戶客製化

第6章 PD-1 和 PD-L1 抑制劑市場：依產品

  • 阿替利珠單抗
  • 阿維魯單抗
  • 度瓦魯單抗
  • 納武單抗
  • 帕博利珠單抗

第7章 PD-1 與 PD-L1 抑制劑市場：依通路

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第8章 美洲PD-1和PD-L1抑制劑市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章 亞太PD-1和PD-L1抑制劑市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲PD-1和PD-L1抑制劑市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭形勢

  • FPNV定位矩陣
  • 市佔率分析：主要企業
  • 競爭情境分析：主要企業

第12章上市公司名單

第13章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-4659C8713657

The Global PD-1 & PD-L1 Inhibitors Market is forecasted to grow significantly, with a projected USD 37.11 billion in 2023 at a CAGR of 20.52% and expected to reach a staggering USD 137.65 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global PD-1 & PD-L1 Inhibitors Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global PD-1 & PD-L1 Inhibitors Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Product, market is studied across Atezolizumab, Avelumab, Durvalumab, Nivolumab, and Pembrolizumab. The Nivolumab is projected to witness significant market share during forecast period.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. The Online Pharmacies is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global PD-1 & PD-L1 Inhibitors Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global PD-1 & PD-L1 Inhibitors Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global PD-1 & PD-L1 Inhibitors Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global PD-1 & PD-L1 Inhibitors Market?

4. What is the competitive strategic window for opportunities in the Global PD-1 & PD-L1 Inhibitors Market?

5. What are the technology trends and regulatory frameworks in the Global PD-1 & PD-L1 Inhibitors Market?

6. What is the market share of the leading vendors in the Global PD-1 & PD-L1 Inhibitors Market?

7. What modes and strategic moves are considered suitable for entering the Global PD-1 & PD-L1 Inhibitors Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. PD-1 & PD-L1 Inhibitors Market, by Product, 2022 vs 2030
  • 4.3. PD-1 & PD-L1 Inhibitors Market, by Distribution Channel, 2022 vs 2030
  • 4.4. PD-1 & PD-L1 Inhibitors Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer coupled with growing geriatric population
      • 5.1.1.2. Growing presence of patient assistance programs
      • 5.1.1.3. Rising public awareness and increasing healthcare expenses
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of cancer immunotherapy
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing research activities in pd1 and pdl1 inhibitors
      • 5.1.3.2. Technological innovations and advancements in cancer screening procedures
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory scenario
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. PD-1 & PD-L1 Inhibitors Market, by Product

  • 6.1. Introduction
  • 6.2. Atezolizumab
  • 6.3. Avelumab
  • 6.4. Durvalumab
  • 6.5. Nivolumab
  • 6.6. Pembrolizumab

7. PD-1 & PD-L1 Inhibitors Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Online Pharmacies
  • 7.4. Retail Pharmacies

8. Americas PD-1 & PD-L1 Inhibitors Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific PD-1 & PD-L1 Inhibitors Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa PD-1 & PD-L1 Inhibitors Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. PD-1 & PD-L1 INHIBITORS MARKET RESEARCH PROCESS
  • FIGURE 2. PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2022 VS 2030 (%)
  • FIGURE 5. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
  • FIGURE 6. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 7. PD-1 & PD-L1 INHIBITORS MARKET DYNAMICS
  • FIGURE 8. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 9. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. PD-1 & PD-L1 INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 15. PD-1 & PD-L1 INHIBITORS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. PD-1 & PD-L1 INHIBITORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 5. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY AVELUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 11. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. PD-1 & PD-L1 INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 101. PD-1 & PD-L1 INHIBITORS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 102. PD-1 & PD-L1 INHIBITORS MARKET LICENSE & PRICING